Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does fluoxetine influence major depression by modifying five-factor personality traits?

Lisheng Du1, David Bakish, Arun V Ravindran

  • 1Institute of Mental Health Research at Royal Ottawa Hospital and University of Ottawa, 1145 Carling Ave., Ottawa, Ontario K1Z 7K4, Canada. ldu@rohcg.on.ca

Journal of Affective Disorders
|August 9, 2002
PubMed
Summary

Major depression patients show distinct personality traits compared to healthy individuals. Fluoxetine treatment improved personality profiles in responders, with Agreeableness predicting treatment success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder: An Individual Participant Data Analysis.

Journal of the American Academy of Child and Adolescent Psychiatry·2026
Same author

Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes périnatals.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2025
Same author

Ti-co-Ce oxide decorated chitosan fiber oxidase mimic identified for portable monitoring of S<sup>2-</sup>, CrO<sub>4</sub><sup>2-</sup> and Fe<sup>2+</sup> assisted with a smartphone.

International journal of biological macromolecules·2024
Same author

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2024
Same author

Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder.

BJPsych open·2024
Same author

Stroke depression: a concept with clinical applicability.

Stroke and vascular neurology·2023

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are established antidepressants, yet predicting patient response remains challenging.
  • Understanding personality differences in major depressive disorder (MDD) and their response to treatment is crucial for personalized medicine.

Purpose of the Study:

  • To compare personality profiles of individuals with MDD against healthy controls.
  • To evaluate the impact of fluoxetine treatment on personality domains in depressed patients.
  • To identify personality traits that may predict antidepressant treatment outcomes.

Main Methods:

  • A cohort of 53 MDD patients and 53 healthy controls were assessed using the NEO-Five-Factor Inventory (NEO-FFI).
  • Assessments were conducted at baseline and after 24 weeks of fluoxetine treatment for the patient group.

Related Experiment Videos

Main Results:

  • Depressed patients exhibited significantly different personality profiles from controls, with higher Neuroticism scores correlating with illness severity.
  • Fluoxetine treatment led to a reversal of high Neuroticism and low Extraversion scores in the overall patient sample and responders.
  • Higher Agreeableness scores were identified as a stronger predictor of treatment outcome than baseline depression severity (HAMD-17).

Conclusions:

  • Significant personality profile differences exist between individuals with MDD and healthy controls.
  • Treatment responders to fluoxetine demonstrated notable shifts in their personality profiles, likely linked to symptom improvement.
  • Limitations include the absence of a placebo group and a moderate sample size, warranting further investigation.